Immunotherapy in pancreatic cancer suffers tremendously from an immunosuppressive microenvironment that is concurrent and, in part, due to extensive desmoplasia. In this work, we present light-responsive liposomes targeted towards the PD-L1 immune checkpoint in pancreatic cancer. Upon light activation, these liposomes induce immunogenic cell death and significantly disrupt tumor collagen to enable self-delivery thought pancreatic tumors developed from genetically engineered mouse model cell isolates. We will discuss the implications of self-delivery of these PD-L1 targeting and blocking liposomes and how the extent of self-delivery through tumors directly correlates with responses to immune checkpoint therapy and overall survival in pancreatic cancer.